There is an urgent need for new antibiotics to treat multidrug-resistant Neisseria gonorrhoeae In this report, the microbiology, in vivo pharmacokinetics, and efficacy of REDX05931, a representative novel tricyclic topoisomerase inhibitor, were evaluated. REDX05931 demonstrated high oral bioavailability in mice and reduced N. gonorrhoeae infection after a single dose in a mouse model of gonorrhea. These data support the potential of this series of small molecules as a new treatment for drug-resistant gonorrheal infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997832 | PMC |
| http://dx.doi.org/10.1128/AAC.00913-16 | DOI Listing |
Publication Analysis
Top Keywords
novel tricyclic
8
tricyclic topoisomerase
8
topoisomerase inhibitor
8
neisseria gonorrhoeae
8
gonorrhoeae infection
8
efficacy novel
4
inhibitor murine
4
murine model
4
model neisseria
4
infection urgent
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!